Source: Annual Congress 2011 - Progress in pathology of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tanaka, N. Ishikawa, N. Hattori, H. Hamada, A. Yokoyama, N. Kohno (Hiroshima, Nankoku, Japan). Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected non-small cell lung cancer. Eur Respir J 2011; 38: Suppl. 55, 1492

Member's Comments

No comment yet.

Related content which might interest you: TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Independent prognostic und predictive value of blood vessel invasion (BVI) in curatively (R0) resected stage II and IIIA non-small cell lung (NSCLC) cancer patients Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001 Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013 Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Survival and clinico-pathologic prognostic factors in surgically resected non-small cell lung carcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 751s Year: 2006 Prognostic parameters in non-small cell lung cancer (211 cases) Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010